Publications by authors named "Seymour de Picciotto"

Article Synopsis
  • Lipid nanoparticle (LNP)-encapsulated mRNA can produce various therapeutic proteins in vivo, facilitating the creation of personalized cancer vaccines and enhancing drug delivery methods.
  • The study demonstrated that mRNA/LNP formulations of specific proteins substantially increased their production and presence in tumors compared to traditional recombinant proteins, with up to 140-fold improvement in exposure over 96 hours.
  • Additionally, these formulations stimulated a stronger immune response, prolonged survival in cancer models, and showed improved efficacy when combined with existing treatments, suggesting potential for better patient outcomes.
View Article and Find Full Text PDF

Interleukin-2 (IL-2) is critical for regulatory T cell (Treg) function and homeostasis. At low doses, IL-2 can suppress immune pathologies by expanding Tregs that constitutively express the high affinity IL-2Rα subunit. However, even low dose IL-2, signaling through the IL2-Rβ/γ complex, may lead to the activation of proinflammatory, non-Treg T cells, so improving specificity toward Tregs may be desirable.

View Article and Find Full Text PDF
Article Synopsis
  • Restoring regulatory T cells (Tregs) is a promising approach for treating neurodegenerative diseases like Parkinson's, showing potential to reduce inflammation and protect neurons.* -
  • A novel lipid nanoparticle (LNP) that delivers mRNA for granulocyte-macrophage colony-stimulating factor (Gm-csf) has been tested in animal models, leading to increased Treg levels and enhanced neuroprotection.* -
  • Results indicated that Gm-csf mRNA treatment not only boosted Treg populations but also reduced neuroinflammation in mice and rats, highlighting its potential for broader applications in neurodegenerative disorders.*
View Article and Find Full Text PDF

Quantifying protein location and concentration is critical for understanding function in situ. Scaffold conjugated to environment-sensitive fluorophore (SuCESsFul) biosensors, in which a reporting fluorophore is conjugated to a binding scaffold, can, in principle, detect analytes of interest with high temporal and spatial resolution. However, their adoption has been limited due to the extensive empirical screening required for their development.

View Article and Find Full Text PDF

Fluorescent probes constitute a valuable toolbox to address a variety of biological questions and they have become irreplaceable for imaging methods. Commonly, such probes consist of fluorescent proteins or small organic fluorophores coupled to biological molecules of interest. Recently, a novel class of fluorescence-based probes, fluorogen-activating proteins (FAPs), has been reported.

View Article and Find Full Text PDF

Yeast surface display is a powerful technology for engineering a broad range of protein scaffolds. This protocol describes the process for de novo isolation of protein binders from large combinatorial libraries displayed on yeast by using magnetic bead separation followed by flow cytometry-based selection. The biophysical properties of isolated single clones are subsequently characterized, and desired properties are further enhanced through successive rounds of mutagenesis and flow cytometry selections, resulting in protein binders with increased stability, affinity, and specificity for target proteins of interest.

View Article and Find Full Text PDF

Reagentless biosensors rely on the interaction of a binding partner and its target to generate a change in fluorescent signal using an environment-sensitive fluorophore or Förster resonance energy transfer. Binding affinity can exert a significant influence on both the equilibrium and the dynamic response characteristics of such a biosensor. We here develop a kinetic model for the dynamic performance of a reagentless biosensor.

View Article and Find Full Text PDF

Yeast surface display (YSD) presents proteins on the surface of yeast through interaction of the agglutinin subunits Aga1p and Aga2p. The human 10th type III fibronectin (Fn3) is a small, 10-kDa protein domain that maintains its native fold without disulfide bonds. A YSD library of Fn3s has been engineered with a loop amino acid composition similar to that of human antibody complementarity-determining region heavy chain loop 3 (CDR-H3) and varying loop lengths, which has been shown to improve binding ability.

View Article and Find Full Text PDF

The ErbB receptor family is dysregulated in many cancers, and its therapeutic manipulation by targeted antibodies and kinase inhibitors has resulted in effective chemotherapies. However, many malignancies remain refractory to current interventions. We describe a new approach that directs ErbB receptor interactions, resulting in biased signaling and phenotypes.

View Article and Find Full Text PDF